StoryOther
Alnylam unveils 'Alnylam 2030' strategy to expand RNAi beyond rare disease into diabetes, obesity, and neurological disorders
At the J.P. Morgan Healthcare Conference, Alnylam's CEO Yvonne Greenstreet announced 'Alnylam 2030,' a five-year strategic plan to advance the company's pipeline and expand RNAi therapeutics into metabolic diseases (type 2 diabetes, obesity) and neurological indications (Huntington's disease, Alzheimer's disease).